Compare · BDX vs PLSE
BDX vs PLSE
Side-by-side comparison of Becton Dickinson and Company (BDX) and Pulse Biosciences Inc (PLSE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and PLSE operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $41.65B, about 23.8x PLSE ($1.75B).
- BDX has been more active in the news (10 items in the past 4 weeks vs 2 for PLSE).
- BDX has more recent analyst coverage (25 ratings vs 6 for PLSE).
- Company
- Becton Dickinson and Company
- Pulse Biosciences Inc
- Price
- -
- -
- Market cap
- $41.65B
- $1.75B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 10
- 2
- Recent ratings
- 25
- 6
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Latest BDX
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Peter Menziuso Named EVP and President, BD Interventional
Latest PLSE
- Canaccord Genuity initiated coverage on Pulse Biosciences with a new price target
- Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Amendment: Director Duggan Robert W bought $12,999,988 worth of shares (660,233 units at $19.69), increasing direct ownership by 1% to 48,370,047 units (SEC Form 4)
- SEC Form 10-Q filed by Pulse Biosciences Inc
- Amendment: SEC Form SCHEDULE 13D/A filed by Pulse Biosciences Inc
- ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million
- Amendment: Chief Executive Officer Laviolette Paul A bought $295,350 worth of shares (15,000 units at $19.69), increasing direct ownership by 1,773% to 15,846 units (SEC Form 4)
- Chief Executive Officer Laviolette Paul A bought $295,350 worth of shares (15,000 units at $19.69) (SEC Form 4)
- Director Duggan Robert W bought $12,999,988 worth of shares (660,233 units at $19.69), increasing direct ownership by 1% to 48,211,433 units (SEC Form 4)
- SEC Form DEF 14A filed by Pulse Biosciences Inc